“EFSA’s recent risk assessments of PFAS, based on epideminological studies, concluded that PFAS affects the immune system at exceptionally low levels of exposure.

A study published in Addiction looks at the use of GLP-1 receptor agonists (Ozempic) for opioid and alcohol addiction. Prof Matt Field, Professor of Psychology, University of Sheffield, said: ...

“The current study studied more than 3 million pregnancies, making it very large by current standards. Importantly, they found no increase in birth defects when men took metformin. This allows us to ...

A study published in JAMA looks at the use of Levonorgestrel-Releasing Intrauterine Systems and breast cancer risk. Prof Amy Berrington, de Gonzalez, Professor of Clinical Cancer Epidemiology, The ...

A perspective piece published in PLOS Medicine looks at ultra-processed foods and public health warnings. Dr Ian Johnson, Nutrition researcher and Emeritus Fellow, Quadram Institute, said: ...

“With many people and places experiencing year on year record temperatures around the globe in the last decade, it is very human to assume global warming is accelerating or ‘surging’. However, through ...

Dr Meilan Huang, Senior Lecturer at the School of Chemistry and Chemical Engineering, Queen’s University Belfast, said: “It’s really exciting news David Baker’s Rosetta and Google Deepmind’s Alphafold ...

A new report from the National Engineering Policy Centre, led by the Royal Academy of Engineering, examines how we can reduce our demand for critical materials and therefore our dependency on imports ...

A new Cochrane review has evaluated the impact of water fluoridation on people’s dental health, looking at studies from multiple decades. Contemporary research, conducted in high-income countries ...

“The storm surge brought about by Milton is (or was) the main worry. Wind speeds did cause considerable damage, but not to the extent that Cat 4 or 5 storms would have. Tampa in particular did escape ...

Dr Simon Cork, Senior Lecturer in Physiology, Anglia Ruskin University (ARU), said: “The planned roll out of tirzepatide marks a key milestone in the future of obesity treatment. Like semaglutide ...